JP2020526503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526503A5 JP2020526503A5 JP2019572539A JP2019572539A JP2020526503A5 JP 2020526503 A5 JP2020526503 A5 JP 2020526503A5 JP 2019572539 A JP2019572539 A JP 2019572539A JP 2019572539 A JP2019572539 A JP 2019572539A JP 2020526503 A5 JP2020526503 A5 JP 2020526503A5
- Authority
- JP
- Japan
- Prior art keywords
- construct
- soluble
- fgf21
- polypeptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 39
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 39
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 210000004962 mammalian cell Anatomy 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 5
- 102100020683 Beta-klotho Human genes 0.000 claims description 4
- 101710104526 Beta-klotho Proteins 0.000 claims description 4
- 230000002124 endocrine Effects 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 108010070675 Glutathione transferase Proteins 0.000 claims description 3
- 229940050528 albumin Drugs 0.000 claims description 3
- 238000007917 intracranial administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 108060008226 thioredoxin Proteins 0.000 claims description 3
- 229940094937 thioredoxin Drugs 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 102100036407 Thioredoxin Human genes 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 17
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 17
- 238000000034 method Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 7
- 108091008794 FGF receptors Proteins 0.000 description 5
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 5
- 210000001723 extracellular space Anatomy 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 102000015834 Klotho Human genes 0.000 description 2
- 108050004036 Klotho Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023083756A JP2023103455A (ja) | 2017-07-06 | 2023-05-22 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529215P | 2017-07-06 | 2017-07-06 | |
| US62/529,215 | 2017-07-06 | ||
| PCT/US2018/040932 WO2019010314A1 (en) | 2017-07-06 | 2018-07-05 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ENDOCRINE FGF-RELATED DISEASES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083756A Division JP2023103455A (ja) | 2017-07-06 | 2023-05-22 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526503A JP2020526503A (ja) | 2020-08-31 |
| JP2020526503A5 true JP2020526503A5 (enExample) | 2021-08-12 |
| JP7316946B2 JP7316946B2 (ja) | 2023-07-28 |
Family
ID=64950347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572539A Active JP7316946B2 (ja) | 2017-07-06 | 2018-07-05 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
| JP2023083756A Pending JP2023103455A (ja) | 2017-07-06 | 2023-05-22 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083756A Pending JP2023103455A (ja) | 2017-07-06 | 2023-05-22 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11365228B2 (enExample) |
| EP (1) | EP3649157A4 (enExample) |
| JP (2) | JP7316946B2 (enExample) |
| CN (1) | CN110997726B (enExample) |
| AU (1) | AU2018297285A1 (enExample) |
| CA (1) | CA3069143A1 (enExample) |
| WO (1) | WO2019010314A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| CN111420030B (zh) * | 2020-05-12 | 2021-01-29 | 江南大学 | Fgf21在制备用于治疗结直肠癌药物中的应用 |
| CN113735960B (zh) * | 2021-03-12 | 2023-04-28 | 江南大学 | 一种fgf重组蛋白治疗nash的应用 |
| CN113105561B (zh) * | 2021-04-30 | 2021-12-03 | 江南大学 | 一种双靶点融合蛋白的制备方法和应用 |
| WO2025059130A1 (en) * | 2023-09-11 | 2025-03-20 | Yale University | Constructs for modulating fgf21/fgfr/beta-klotho signaling pathway and treating diseases and disorders, and methods thereof |
| CN118852466B (zh) * | 2024-08-08 | 2025-03-28 | 郑州大学第三附属医院(河南省妇幼保健院) | Klotho修饰的CAR-T结构及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| LT2550972T (lt) * | 2007-04-02 | 2018-05-10 | Genentech, Inc. | Kloto-beta agonistinis antikūnas, skirtas cukrinio diabeto arba atsparumo insulinui gydymui |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質 |
| CA2835101A1 (en) * | 2011-05-10 | 2012-11-15 | Amgen Inc. | Method of identifying compounds that specifically modulate the interaction of fgfr1 and .beta.-klotho |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| WO2013027191A1 (en) * | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
| WO2013131091A1 (en) * | 2012-03-02 | 2013-09-06 | New York University | Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders |
| US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
| US9400677B2 (en) | 2013-01-02 | 2016-07-26 | Apple Inc. | Adaptive handling of priority inversions using transactions |
| WO2015138278A1 (en) | 2014-03-11 | 2015-09-17 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| CA2969307A1 (en) | 2014-12-04 | 2016-06-09 | Novartis Ag | Methods and compositions using klotho variant polypeptides |
| WO2016204884A1 (en) * | 2015-06-18 | 2016-12-22 | Albert Einstein College Of Medicine, Inc. | Fgf receptor ligands for treating diabetes and obesity |
| EP3371217B1 (en) * | 2015-11-08 | 2025-06-11 | F. Hoffmann-La Roche AG | Methods of screening for multispecific antibodies |
| US20190142963A1 (en) * | 2016-04-15 | 2019-05-16 | Richard D. DiMarchi | Fgf21 c-terminal peptide optimization |
| JP7023518B2 (ja) | 2016-05-25 | 2022-02-22 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 分泌障害の処置のための方法および組成物 |
| WO2018026899A1 (en) * | 2016-08-03 | 2018-02-08 | Joslin Diabetes Center, Inc. | Methods and compositions for treating hypoglycemia |
-
2018
- 2018-07-05 EP EP18827563.0A patent/EP3649157A4/en active Pending
- 2018-07-05 CA CA3069143A patent/CA3069143A1/en active Pending
- 2018-07-05 US US16/624,895 patent/US11365228B2/en active Active
- 2018-07-05 WO PCT/US2018/040932 patent/WO2019010314A1/en not_active Ceased
- 2018-07-05 AU AU2018297285A patent/AU2018297285A1/en not_active Abandoned
- 2018-07-05 JP JP2019572539A patent/JP7316946B2/ja active Active
- 2018-07-05 CN CN201880054775.3A patent/CN110997726B/zh active Active
-
2023
- 2023-02-28 US US18/176,172 patent/US20240083961A1/en active Pending
- 2023-05-22 JP JP2023083756A patent/JP2023103455A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526503A5 (enExample) | ||
| JP2020500885A5 (enExample) | ||
| JP5199876B2 (ja) | 一価ＩｇＧを生成するための方法 | |
| JP7575862B2 (ja) | デュアル機能タンパク質およびそれを含む医薬組成物 | |
| US9708412B2 (en) | Trispecific binding proteins and methods of use | |
| JP5564268B2 (ja) | 成長因子と結合する融合タンパク質 | |
| ES2677111T3 (es) | Mejora del transporte de moléculas terapéuticas a través de la barrera hematoencefálica | |
| JP2023103455A5 (enExample) | ||
| CN110121355B (zh) | 用于预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物 | |
| CN103965363B (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP4398644B2 (ja) | ＥｒｂＢ界面ペプチド擬態およびその使用方法 | |
| CN116987189A (zh) | 单链可变片段cd3结合蛋白质 | |
| CN102666586A (zh) | 具有延长的半衰期的药物融合体和缀合物 | |
| TW202035440A (zh) | 新穎合理設計的蛋白質組合物 | |
| JP2012507299A (ja) | Ｌｉｇｈｔ標的分子およびその使用 | |
| JP2016532448A (ja) | Ｇｌｐ−１ｒに特異的に結合する抗体およびそのｇｌｐ−１との融合タンパク質 | |
| JP2008500373A5 (enExample) | ||
| Kliwinski et al. | Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice | |
| WO2020221198A1 (zh) | 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体 | |
| JP7649923B2 (ja) | ＧＰＣ３標的化抗体インターフェロンα融合タンパク質及びその使用 | |
| US20120058116A1 (en) | Fgfr1c antibody combinations | |
| TWI723247B (zh) | 重組蛋白及其用途 | |
| JP2023546758A (ja) | アクチビンおよび腫瘍壊死因子－アルファの二機能性アンタゴニストならびにその使用 | |
| RU2836245C2 (ru) | БЕЛОК СЛИЯНИЯ НАЦЕЛЕННОГО НА GPC3 АНТИТЕЛА И ИНТЕРФЕРОНА α И ЕГО ПРИМЕНЕНИЕ | |
| JPWO2021247604A5 (enExample) |